drug · antibody

IMDELLTRA

updated 2mo ago

by $AMGN AMGEN INC🔗 ChEMBL

community read0 votes

Antibody drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 3 investigational indications.

targets

Delta-like protein 3T cell surface glycoprotein CD3

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

IMDELLTRA

trade names

Imdelltra

generic

TARLATAMAB-DLLE

MOA

12.1 Mechanism of Action Tarlatamab-dlle is a bispecific T-cell engager that binds to DLL3 expressed on the surface of cells, including tumor cells, and CD3 expressed on the surface of T cells. Tarlatamab-dlle causes T-cell activation, release of inflammatory cytokines, and lysis of DLL3-expressing cells. Tarlatamab-dlle had anti-tumor activity in mouse models of SCLC.

indication

1 INDICATIONS AND USAGE IMDELLTRA is indicated for the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. IMDELLTRA is a bispecific delta-like ligand 3 (DLL3)-directed CD3 T- cell engager indicated for the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum - based chemotherapy. ( 1 )

IMDELLTRA

targets

all catalysts(0)

News(0)

Report a data issue

comments(0)

🐶 often sniffed alongside